Gemcitabine and Pemetrexed disodium in treating breast cancer

Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):34-7.

Abstract

Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase. This agent is broadly active in a wide variety of solid tumors, including breast cancer. Pemetrexed disodium has also shown clinically relevant activity in combination with gemcitabine (Gemzar). This combination is being evaluated for the treatment of metastatic breast cancer.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use*
  • Female
  • Folic Acid Antagonists / adverse effects
  • Folic Acid Antagonists / therapeutic use
  • Gemcitabine
  • Glutamates / administration & dosage
  • Glutamates / adverse effects
  • Glutamates / therapeutic use*
  • Guanine / administration & dosage
  • Guanine / adverse effects
  • Guanine / analogs & derivatives*
  • Guanine / therapeutic use*
  • Humans
  • Neoplasm Metastasis
  • Pemetrexed

Substances

  • Folic Acid Antagonists
  • Glutamates
  • Pemetrexed
  • Deoxycytidine
  • Guanine
  • Gemcitabine